Commerce Bank decreased its position in Allergan PLC (NYSE:AGN) by 2.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 104,019 shares of the company’s stock after selling 3,127 shares during the period. Commerce Bank’s holdings in Allergan PLC were worth $23,956,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of AGN. Ladenburg Thalmann Financial Services Inc. increased its position in Allergan PLC by 18.5% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,095 shares of the company’s stock worth $2,438,000 after buying an additional 1,423 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new position in Allergan PLC during the first quarter worth approximately $668,000. Barnett & Company Inc. acquired a new position in Allergan PLC during the first quarter worth approximately $111,000. Boothbay Fund Management LLC acquired a new position in Allergan PLC during the first quarter worth approximately $378,000. Finally, Kistler Tiffany Companies LLC increased its position in Allergan PLC by 2.2% in the second quarter. Kistler Tiffany Companies LLC now owns 920 shares of the company’s stock worth $213,000 after buying an additional 20 shares in the last quarter. Institutional investors own 89.21% of the company’s stock.
Shares of Allergan PLC (NYSE:AGN) traded down 0.45% during trading on Friday, hitting $192.22. 1,224,575 shares of the stock were exchanged. Allergan PLC has a 52 week low of $184.50 and a 52 week high of $322.68. The firm has a market capitalization of $72.10 billion, a price-to-earnings ratio of 5.39 and a beta of 1.08. The stock’s 50 day moving average price is $214.61 and its 200 day moving average price is $233.51.
Allergan PLC (NYSE:AGN) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported $3.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.65 by $0.33. The business earned $3.62 billion during the quarter, compared to the consensus estimate of $3.73 billion. Allergan PLC had a return on equity of 7.26% and a net margin of 93.74%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.48 earnings per share. On average, equities analysts predict that Allergan PLC will post $13.37 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 28th. Investors of record on Tuesday, February 28th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.46%. This is a positive change from Allergan PLC’s previous quarterly dividend of $0.05.
AGN has been the subject of a number of recent research reports. Vetr upgraded shares of Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $285.60 price objective for the company in a research note on Monday, August 1st. Credit Suisse Group AG set a $322.00 price objective on shares of Allergan PLC and gave the stock a “hold” rating in a research note on Wednesday, August 3rd. Mizuho upped their target price on shares of Allergan PLC from $232.00 to $246.00 and gave the company a “neutral” rating in a report on Friday, August 5th. JPMorgan Chase & Co. set a $325.00 target price on shares of Allergan PLC and gave the company a “buy” rating in a report on Friday, August 5th. Finally, Royal Bank Of Canada dropped their target price on shares of Allergan PLC from $307.00 to $300.00 and set an “outperform” rating on the stock in a report on Tuesday, August 9th. Seven research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $289.11.
In other news, CEO Brent L. Saunders acquired 5,250 shares of Allergan PLC stock in a transaction on Monday, November 21st. The stock was acquired at an average cost of $189.13 per share, for a total transaction of $992,932.50. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Maria Teresa Hilado acquired 1,422 shares of Allergan PLC stock in a transaction on Friday, November 11th. The shares were purchased at an average price of $210.64 per share, with a total value of $299,530.08. Following the completion of the purchase, the chief financial officer now owns 12,659 shares in the company, valued at approximately $2,666,491.76. The disclosure for this purchase can be found here. 0.27% of the stock is currently owned by corporate insiders.
Allergan PLC Company Profile